Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: TAMOXIFEN - ADVERSE EFFECTS , . Treffer: 6
2013
Pfeiler, G; Stöger, H; Dubsky, P; Mlineritsch, B; Singer, C; Balic, M; Fitzal, F; Moik, M; Kwasny, W; Selim, U; Renner, K; Ploner, F; Steger, GG; Seifert, M; Hofbauer, F; Sandbichler, P; Samonigg, H; Jakesz, R; Greil, R; Fesl, C; Gnant, M; ABCSG
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Br J Cancer. 2013; 108(7):1408-1414
Doi: 10.1038/bjc.2013.114
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2012
Dubsky, PC; Jakesz, R; Mlineritsch, B; Pöstlberger, S; Samonigg, H; Kwasny, W; Tausch, C; Stöger, H; Haider, K; Fitzal, F; Singer, CF; Stierer, M; Sevelda, P; Luschin-Ebengreuth, G; Taucher, S; Rudas, M; Bartsch, R; Steger, GG; Greil, R; Filipcic, L; Gnant, M
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
J Clin Oncol. 2012; 30(7):722-728
Doi: 10.1200/JCO.2011.36.8993
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2009
Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Pöstlberger, S; Menzel, C; Jakesz, R; Seifert, M; Hubalek, M; Bjelic-Radisic, V; Samonigg, H; Tausch, C; Eidtmann, H; Steger, G; Kwasny, W; Dubsky, P; Fridrik, M; Fitzal, F; Stierer, M; Rücklinger, E; Greil, R; ABCSG-12 Trial Investigators; Marth, C
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
N Engl J Med. 2009; 360(7):679-691
Doi: 10.1056/NEJMoa0806285
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2007
Gnant, MF; Mlineritsch, B; Luschin-Ebengreuth, G; Grampp, S; Kaessmann, H; Schmid, M; Menzel, C; Piswanger-Soelkner, JC; Galid, A; Mittlboeck, M; Hausmaninger, H; Jakesz, R; Austrian Breast and Colorectal Cancer Study Group
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
J Clin Oncol. 2007; 25(7): 820-828.
Doi: 10.1200/JCO.2005.02.7102
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Moinfar, F; Azodi, M; Tavassoli, FA
Uterine sarcomas.
PATHOLOGY. 2007; 39(1): 55-71.
Doi: 10.1080/00313020601136146
Web of Science
PubMed
FullText
FullText_MUG
2005
Jakesz, R; Jonat, W; Gnant, M; Mittlboeck, M; Greil, R; Tausch, C; Hilfrich, J; Kwasny, W; Menzel, C; Samonigg, H; Seifert, M; Gademann, G; Kaufmann, M
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Lancet. 2005; 366(9484):455-462
Doi: 10.1016/S0140-6736(05)67059-6
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar